Design Therapeutics (NASDAQ:DSGN) Stock Rating Reaffirmed by Royal Bank of Canada

Royal Bank of Canada reaffirmed their sector perform rating on shares of Design Therapeutics (NASDAQ:DSGNFree Report) in a research note issued to investors on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has a $4.00 price target on the stock.

Separately, Wedbush reissued a neutral rating and set a $5.00 price objective on shares of Design Therapeutics in a research report on Wednesday. Seven investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of Hold and a consensus target price of $5.50.

Read Our Latest Analysis on Design Therapeutics

Design Therapeutics Stock Performance

DSGN opened at $3.80 on Wednesday. The firm’s fifty day moving average is $2.60 and its two-hundred day moving average is $2.45. Design Therapeutics has a twelve month low of $1.94 and a twelve month high of $8.47. The firm has a market cap of $214.68 million, a PE ratio of -3.17 and a beta of 1.72.

Institutional Trading of Design Therapeutics

A number of large investors have recently added to or reduced their stakes in DSGN. Legal & General Group Plc lifted its stake in shares of Design Therapeutics by 28.0% during the 2nd quarter. Legal & General Group Plc now owns 3,247 shares of the company’s stock worth $45,000 after buying an additional 711 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Design Therapeutics by 11.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,173 shares of the company’s stock worth $96,000 after buying an additional 1,546 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Design Therapeutics by 4.1% during the 1st quarter. Bank of America Corp DE now owns 57,199 shares of the company’s stock worth $924,000 after buying an additional 2,262 shares during the last quarter. American International Group Inc. lifted its stake in shares of Design Therapeutics by 20.1% during the 2nd quarter. American International Group Inc. now owns 15,859 shares of the company’s stock worth $222,000 after buying an additional 2,657 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Design Therapeutics by 48.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 9,010 shares of the company’s stock worth $151,000 after buying an additional 2,951 shares during the last quarter. Institutional investors and hedge funds own 69.47% of the company’s stock.

About Design Therapeutics

(Get Free Report)

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Read More

Analyst Recommendations for Design Therapeutics (NASDAQ:DSGN)

Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.